JNJ vs MRNA
By Alex · Tickerpine
Johnson & Johnson vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | MRNA |
|---|---|---|
| Price | $285.75 | $223.37 |
| Market cap | $687.89B | $90.38B |
| P/E ratio | 43.4 | — |
| ROE | 20.02% | -34.50% |
| Profit margin | 16.20% | -110.45% |
| Revenue growth | 5.90% | 29.20% |
| Dividend yield | 1.88% | 0.00% |
| Beta | 0.20 | 1.17 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs MRNA in plain English
- JNJ is the bigger company — about 7.6× the market cap of MRNA.
- JNJ earns a higher return on equity (20% vs -35%).
- MRNA is growing revenue faster (29% vs 6%).
- JNJ pays a dividend (1.88%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.